PHS2021-1

Research approvals granted prior to January 21, 2019 comply with previous policy. However, when there is a compelling reason to transition the research, the IRB or an investigator may amend the research to comply with this version of the policy on or after January 21, 2019. ... If a clinician wishes to use an FDA approved drug/biologic off ... ................
................